Data from Effects of <i>BRCA1</i>- and <i>BRCA2</i>-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis

Abstract

<div>Abstract<p><b>Purpose:</b> To estimate the effects of <i>BRCA1</i> and <i>BRCA2</i> mutations on ovarian cancer and breast cancer survival.</p><p><b>Experimental Design:</b> We searched PubMed and EMBASE for studies that evaluated the associations between <i>BRCA</i> mutations and ovarian or breast cancer survival. Meta-analysis was conducted to generate combined HRs with 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS).</p><p><b>Results:</b> From 1,201 unique citations, we identified 27 articles that compared prognosis between <i>BRCA</i> mutation carriers and noncarriers in patients with ovarian or breast cancer. Fourteen studies examined ovarian cancer survival and 13 studies examined breast cancer survival. For ovarian cancer, meta-analysis demonstrated that both <i>BRCA1</i> and <i>BRCA2</i> mutation carriers had better OS (HR, 0.76; 95% CI, 0.70–0.83 for <i>BRCA1</i> mutation carriers; HR, 0.58; 95% CI, 0.50–0.66 for <i>BRCA2</i> mutation carriers) and PFS (HR, 0.65; 95% CI, 0.52–0.81 for <i>BRCA1</i> mutation carriers; HR, 0.61; 95% CI, 0.47–0.80 for <i>BRCA2</i> mutation carriers) than noncarriers, regardless of tumor stage, grade, or histologic subtype. Among patients with breast cancer, <i>BRCA1</i> mutation carriers had worse OS (HR, 1.50; 95% CI, 1.11–2.04) than noncarriers but were not significantly different from noncarriers in PFS. <i>BRCA2</i> mutation was not associated with breast cancer prognosis.</p><p><b>Conclusions:</b> Our analyses suggest that <i>BRCA</i> mutations are robust predictors of outcomes in both ovarian and breast cancers and these mutations should be taken into account when devising appropriate therapeutic strategies. <i>Clin Cancer Res; 21(1); 211–20. ©2014 AACR</i>.</p></div>